Glaukos Corporation has released an investor presentation detailing its ongoing strategy as a hybrid pharmaceutical-device company focused on advancing new technologies for chronic eye diseases. The presentation highlights the company’s efforts to address unmet needs in ocular hypertension, open-angle glaucoma, keratoconus, and other eye conditions. Glaukos reports a 30% topline growth for 2025 and a 20% ten-year revenue CAGR, with an investment in research and development since 2018. Key developments include advancements in interventional glaucoma therapies, such as the iDose TR, which delivers long-duration drug therapy for up to three years to address patient non-compliance with eye drops. The company is also progressing with additional iDose platform products, including iDose TRIO and iDose TREX, designed to further expand treatment options and ease of use. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief on January 13, 2026, and is solely responsible for the information contained therein.